Literature DB >> 24493699

Suppression of spontaneous ca elevations prevents atrial fibrillation in calsequestrin 2-null hearts.

Michela Faggioni1, Eleonora Savio-Galimberti, Raghav Venkataraman, Hyun Seok Hwang, Prince J Kannankeril, Dawood Darbar, Björn C Knollmann.   

Abstract

BACKGROUND: Atrial fibrillation (AF) risk has been associated with leaky ryanodine receptor 2 (RyR2) Ca release channels. Patients with mutations in RyR2 or in the sarcoplasmic reticulum Ca-binding protein calsequestrin 2 (Casq2) display an increased risk for AF. Here, we examine the underlying mechanisms of AF associated with loss of Casq2 and test mechanism-based drug therapy. METHODS AND
RESULTS: Compared with wild-type Casq2+/+ mice, atrial burst pacing consistently induced atrial flutter or AF in Casq2-/- mice and in isolated Casq2-/- hearts. Atrial optical voltage maps obtained from isolated hearts revealed multiple independent activation sites arising predominantly from the pulmonary vein region. Ca and voltage mapping demonstrated diastolic subthreshold spontaneous Ca elevations (SCaEs) and delayed afterdepolarizations whenever the pacing train failed to induce AF. The dual RyR2 and Na channel inhibitor R-propafenone (3 μmol/L) significantly reduced frequency and amplitude of SCaEs and delayed afterdepolarizations in atrial myocytes and intact atria and prevented induction of AF. In contrast, the S-enantiomer of propafenone, an equipotent Na channel blocker but much weaker RyR2 inhibitor, did not reduce SCaEs and delayed afterdepolarizations and failed to prevent AF.
CONCLUSIONS: Loss of Casq2 increases risk of AF by promoting regional SCaEs and delayed afterdepolarizations in atrial tissue, which can be prevented by RyR2 inhibition with R-propafenone. Targeting AF caused by leaky RyR2 Ca channels with R-propafenone may be a more mechanism-based approach to treating this common arrhythmia.

Entities:  

Keywords:  atrial fibrillation; calsequestrin 2; delayed afterdepolarization; propafenone; ryanodine receptor calcium release channel; tachycardia, ventricular

Mesh:

Substances:

Year:  2014        PMID: 24493699      PMCID: PMC3989424          DOI: 10.1161/CIRCEP.113.000994

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  29 in total

1.  Effects of propafenone on K currents in human atrial myocytes.

Authors:  A Seki; N Hagiwara; H Kasanuki
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

2.  Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation.

Authors:  Ali El-Armouche; Peter Boknik; Thomas Eschenhagen; Lucie Carrier; Michael Knaut; Ursula Ravens; Dobromir Dobrev
Journal:  Circulation       Date:  2006-08-07       Impact factor: 29.690

3.  Stereoselective disposition and pharmacologic activity of propafenone enantiomers.

Authors:  H K Kroemer; C Funck-Brentano; D J Silberstein; A J Wood; M Eichelbaum; R L Woosley; D M Roden
Journal:  Circulation       Date:  1989-05       Impact factor: 29.690

4.  Defective cardiac ryanodine receptor regulation during atrial fibrillation.

Authors:  John A Vest; Xander H T Wehrens; Steven R Reiken; Stephan E Lehnart; Dobromir Dobrev; Parag Chandra; Peter Danilo; Ursula Ravens; Michael R Rosen; Andrew R Marks
Journal:  Circulation       Date:  2005-04-26       Impact factor: 29.690

5.  Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach.

Authors:  Paolo Alboni; Giovanni L Botto; Nicola Baldi; Mario Luzi; Vitantonio Russo; Lorella Gianfranchi; Paola Marchi; Massimo Calzolari; Alberto Solano; Raffaele Baroffio; Germano Gaggioli
Journal:  N Engl J Med       Date:  2004-12-02       Impact factor: 91.245

6.  Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes.

Authors:  Leif Hove-Madsen; Anna Llach; Antoni Bayes-Genís; Santiago Roura; Enrique Rodriguez Font; Alejandro Arís; Juan Cinca
Journal:  Circulation       Date:  2004-08-16       Impact factor: 29.690

7.  Lifetime risk for development of atrial fibrillation: the Framingham Heart Study.

Authors:  Donald M Lloyd-Jones; Thomas J Wang; Eric P Leip; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Ralph B D'Agostino; Joseph M Massaro; Alexa Beiser; Philip A Wolf; Emelia J Benjamin
Journal:  Circulation       Date:  2004-08-16       Impact factor: 29.690

Review 8.  Genetic mechanisms of atrial fibrillation: impact on response to treatment.

Authors:  Dawood Darbar; Dan M Roden
Journal:  Nat Rev Cardiol       Date:  2013-04-16       Impact factor: 32.419

9.  Effects of propafenone on calcium currents in single ventricular myocytes of guinea-pig.

Authors:  L Fei; J S Gill; W J McKenna; A J Camm
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

10.  Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Silvia G Priori; Carlo Napolitano; Mirella Memmi; Barbara Colombi; Fabrizio Drago; Maurizio Gasparini; Luciano DeSimone; Fernando Coltorti; Raffaella Bloise; Roberto Keegan; Fernando E S Cruz Filho; Gabriele Vignati; Abraham Benatar; Angelica DeLogu
Journal:  Circulation       Date:  2002-07-02       Impact factor: 29.690

View more
  33 in total

Review 1.  Calcium-mediated cellular triggered activity in atrial fibrillation.

Authors:  Dobromir Dobrev; Xander H T Wehrens
Journal:  J Physiol       Date:  2017-03-22       Impact factor: 5.182

Review 2.  The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics: Is Personalized Therapy in Sight?

Authors:  Dawood Darbar
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

Review 3.  Genotype influence in responses to therapy for atrial fibrillation.

Authors:  Henry Huang; Dawood Darbar
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-07-15

Review 4.  Sinus node dysfunction in catecholaminergic polymorphic ventricular tachycardia: risk factor and potential therapeutic target?

Authors:  Michela Faggioni; Christian van der Werf; Bjorn C Knollmann
Journal:  Trends Cardiovasc Med       Date:  2014-07-10       Impact factor: 6.677

5.  Altered calcium handling produces reentry-promoting action potential alternans in atrial fibrillation-remodeled hearts.

Authors:  Tao Liu; Feng Xiong; Xiao-Yan Qi; Jiening Xiao; Louis Villeneuve; Issam Abu-Taha; Dobromir Dobrev; Congxin Huang; Stanley Nattel
Journal:  JCI Insight       Date:  2020-04-07

6.  Alternating membrane potential/calcium interplay underlies repetitive focal activity in a genetic model of calcium-dependent atrial arrhythmias.

Authors:  Qing Lou; Andriy E Belevych; Przemysław B Radwański; Bin Liu; Anuradha Kalyanasundaram; Bjorn C Knollmann; Vadim V Fedorov; Sándor Györke
Journal:  J Physiol       Date:  2014-12-02       Impact factor: 5.182

7.  Calcium in atrial fibrillation - pulling the trigger or not?

Authors:  Nieves Gomez-Hurtado; Björn C Knollmann
Journal:  J Clin Invest       Date:  2014-10-20       Impact factor: 14.808

Review 8.  Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.

Authors:  Matthew J Wleklinski; Prince J Kannankeril; Bjӧrn C Knollmann
Journal:  J Physiol       Date:  2020-04-27       Impact factor: 5.182

9.  Ion Channel and Structural Remodeling in Obesity-Mediated Atrial Fibrillation.

Authors:  Mark D McCauley; Liang Hong; Arvind Sridhar; Ambili Menon; Srikanth Perike; Meihong Zhang; Ivson Bezerra da Silva; JiaJie Yan; Marcelo G Bonini; Xun Ai; Jalees Rehman; Dawood Darbar
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-07-12

10.  Targeting pathological leak of ryanodine receptors: preclinical progress and the potential impact on treatments for cardiac arrhythmias and heart failure.

Authors:  Patrick Connell; Tarah A Word; Xander H T Wehrens
Journal:  Expert Opin Ther Targets       Date:  2020-01-03       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.